Results for this period
Interim period (second quarter)1 April 2026–30 September 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from the regenerative medicine products business increased due to the expansion of Jasmine’s adoption across facilities and the increase in the number of cases, as well as broader use of Jack at existing facilities and its introduction at new facilities. Revenue from the regenerative medicine contract services business declined as the education and know-how provision projects carried out in the previous fiscal year ran their course.
There are no applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 April 2026–30 September 2026 |
| Net Sales | ¥1,499 million (YoY +50.1%) |
| Operating profit | ¥0 million |
| Ordinary income | ¥7 million |
| Profit attributable to owners of the parent | ¥4 million |
| Net income per share | ¥0.10 |
| Equity ratio | End of the current fiscal period 88.3 / End of previous period 89.6 |
| Total assets | ¥5,770 million |
| Net assets | ¥5,094 million |
| Cash flows from operating activities | ¥152,053 thousand |
| Cash flows from investing activities | ¥-172,956 thousand |
| Cash flows from financing activities | ¥0 thousand |
| Cash and cash equivalents at end of period | ¥1,429,561 thousand |
| Full-year earnings forecast | Net Sales ¥3,070 million (YoY +40.6%) / Operating profit ¥100 million / Ordinary income ¥110 million / Net income ¥100 million |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Segment revenue | Regenerative medicine products business ¥1,144,118 thousand (YoY +80.6%), Regenerative medicine contract services business ¥215,721 thousand (YoY -5.1%), Labsite business ¥139,184 thousand (YoY +1.0%) |
| Segment profit | Regenerative medicine products business ¥405,828 thousand, Regenerative medicine contract services business ¥117,774 thousand, Labsite business ¥23,487 thousand |
| Depreciation and amortization | ¥68,610 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Subsidy Income ¥2,725 thousand / Extraordinary loss Loss on reduction of fixed assets ¥2,725 thousand |
| Disclosure regarding the going concern assumption | There are no applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Established the local consolidated subsidiary Japan Tissue Engineering Europe GmbH in October 2026. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 40,610,200 |
| Treasury Shares at Period-End | 250 |
| Factors Behind Changes in Business Performance | Revenue from the regenerative medicine products business increased due to the expansion of Jasmine’s adoption across facilities and the increase in the number of cases, as well as broader use of Jack at existing facilities and its introduction at new facilities. Revenue from the regenerative medicine contract services business declined as the education and know-how provision projects carried out in the previous fiscal year ran their course. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue from the regenerative medicine products business increased 80.6%. The expansion of Jasmine’s adoption across facilities and the increase in the number of cases, along with broader use of Jack at existing facilities and its introduction at new facilities, contributed to revenue growth. Meanwhile, revenue from the regenerative medicine contract services business declined as the education and know-how provision projects carried out in the previous fiscal year ran their course.